To evaluate the efficacy and safety of oral ICP-332 in adults with moderate to severe atopic dermatitis (AD).
Key Findings:
Mean EASI reductions were 78% for the 80-mg dose and 73% for the 120-mg dose, compared to 17% for placebo.
64% of patients in both ICP-332 groups achieved an EASI 75 response versus 8% with placebo.
Improvements in pruritus were observed as early as day 2.
Interpretation:
ICP-332 monotherapy demonstrated significant efficacy and a favorable safety profile in treating moderate to severe AD, warranting further investigation in larger trials.
Limitations:
Small sample size and short treatment duration limit long-term efficacy assessment.
All participants were of Asian descent, affecting generalizability.
No active comparators or subgroup analyses were included.
Conclusion:
The study supports the initiation of larger phase 3 trials to confirm ICP-332's effectiveness in AD treatment.
